Official UK procurement notice
NP49124 Hepatitis C Medicines
Authority: NHS Scotland (NHS & healthcare)
What is being bought3 lots · detail below
Published requirement descriptionSupply of Hepatitis C Medicines to NHS Scotland.
CPV: Pharmaceutical products
How this framework works
From the published notice- Places
- up to 3 suppliers · 3 bids on the busiest of 3 lots (1.0 per place) · 3 appointed (full)
Lots and requirements (3)Procurement structure
3 lots · 1 with a published valueLot #1Hepatitis C - Treatment Cost per MedicineAwardedRenewalPublished value£35,791,085
Supply of Hepatitis C Medicines to NHS Scotland. The Authority has awarded this Lot as a single supplier framework per line to one (1) Framework Participant.
Lot #2Hepatitis C Medicines - Price submitted based on Volume (unscored)AwardedRenewalLot estimate not published
Supply of Hepatitis C to NHS Scotland to NHS Scotland. The Authority has awarded this Lot as a unranked multi-supplier framework per line to two (2) Framework Participants.
Please note II.2.5) Award criteria is not applicable. This was an unscored Lot. Additional information: Please note II.2.5) Award criteria is not applicable as this is an unscored lot.
Lot #3Hepatitis C Medicines - Price submitted based on Volume (unscored)AwardedRenewalLot estimate not published
Supply of Hepatitis C to NHS Scotland to NHS Scotland. The Authority has awarded this Lot as a unranked multi-supplier framework per line to two (2) Framework Participants.
Please note II.2.5) Award criteria is not applicable. This was an unscored Lot. Additional information: Please note II.2.5) Award criteria is not applicable. This was an unscored Lot.
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Published sub-criteria (3)
- Treatment duration: 2.5%
- Genotype testing: 2.5%
- price: 95%
Published award criteria (3)
- Treatment duration: 2.5
- Genotype testing: 2.5
- Price: 95
- Technical & professional ability
(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation (PL, PLGB, or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender of the Framework Agreement.
(b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.
(c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design.
Minimum: (a) Confirmation of existence of a valid and current UK Marketing Authorisation (PL, PLGB, PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender of the Framework Agreement should be included in the Qualification Envelop…
- Price carries 95 of 100 points: a 10% discount moves about 9.5 points. This one is won on the number: sharpen the price before polishing the prose.
- “NP49124 Hepatitis C Medicines” is a framework: the contest is a place on its panel, up to 3 suppliers, not a single contract.
Price arithmetic assumes straight proportional scoring; the tender pack may use another formula.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- No (one-off requirement)
- First published
- 1 Dec 2023, 09:00 GMT
- Last source update
- 21 Mar 2024, 12:15 GMT
- Award evaluation window
- 12 Jan 2024 – …
- FTS notice number
2024/S 000-009172- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-041e33Find a Tender
- Electronic trading
- e-invoicing allowed · electronic ordering · electronic payment
- Review procedure
Economic operators should approach the contracting authority in the first instance. However, the only formal remedy is to apply to the courts:
An economic operator that suffers, or is at risk of suffering, loss, or damage attributable to a breach of duty under the Public Contracts (Scotland) Regulations 2015 or the Procurement Reform (Scotland) Act 2014, may bring proceedings in the Sheriff Court or the Court of Session.
The bringing of court proceedings against the Authority after the Framework Agreement has been entered into will not affect the Framework Agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the Framework Agreement has been entered into are limited to the award of damages.
Publisher note: The estimated value(s) referred to in Section section II.I.7 and Section V.2.4 and within all Lots cover(s) the twenty-four (24) month contract duration and the forty-eight (48) month extension period of the framework agreement. (SC Ref:761578)
How it was run
Official notice- Appointment period ends
- 12 Jan 2024, 12:00 GMT
- Submission channel
- {"electronicSubmission"}
- Accepted languages
- en
- Bid validity
- 90 days from the deadline
- Bids opened
- 12 Jan 2024, 12:00 GMT
Timeline
12 Jan 2024 → 21 Mar 2024 · 3 dates- Admission / appointment period endsperiod end, not a bid countdown12 Jan 2024, 12:00 GMT
- Bids opened12 Jan 2024, 12:00 GMT
- Notice published21 Mar 2024, 12:15 GMT
Notice history
1 event · 2 releases on Find a Tender- Status changed to complete21 Mar 2024, 12:15 GMT
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast3 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.
Contracts
All 2 of these contracts carry the same published figure, £1, the framework's maximum for the whole notice, not each contract's own value. They are not eleven separate sums.
Hepatitis C - Treatment Cost per Medicine
- Signed
- 27 Feb 2024
- Value
- £36,556,080
- Status
- active
Hepatitis C Medicines - Price submitted based on Volume (unscored)
- Signed
- 27 Feb 2024
- Value
- ceiling above
- Status
- active
Hepatitis C Medicines - Price submitted based on Volume (unscored)
- Signed
- 27 Feb 2024
- Value
- ceiling above
- Status
- active
Bid statistics published by the authority
| Lot | Bids | SME | VCSE | Valid bid range |
|---|---|---|---|---|
| 1 · Hepatitis C - Treatment Cost per Medicine | 3bids · 3 electronic · 3 from abroad | 0 | — | — |
| 2 · Hepatitis C Medicines - Price submitted based on Volume (unscored) | 2bids · 2 electronic · 2 from abroad | 0 | — | — |
| 3 · Hepatitis C Medicines - Price submitted based on Volume (unscored) | 2bids · 2 electronic · 2 from abroad | 0 | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Sheriff Court HouseReview body
Framework contractors & participating bidders
3 commercial parties on the notice- AbbVie LtdFramework contractor
- Gilead Sciences LtdFramework contractor
- Merck Sharp & Dohme UK LtdFramework contractor
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.